ORAMED PHARMACEUTICALS INC.(ORMP)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,105 of 2,879 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
ORMP Stock Analysis & AI Quality Score
AI stock analysis and institutional research for ORAMED PHARMACEUTICALS INC. (ORMP), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ORMP at 56.3/100 on a 32-signal composite quality model, placing it at rank #1,105 of 2,879 stocks — the top half of the AI-ranked universe. ORMP scores in the top quartile across profitability (99.6), balance sheet strength (99.3), revenue growth (85.9). Areas of concern include revenue scale (1.7) and free cash flow (4.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), ORAMED PHARMACEUTICALS INC. reports net income of $38.3M, free cash flow of $-2.9M. Top institutional holders of ORMP by reported 13-F value include BML Capital Management,, Aquamarine Financial (Cayman) Ltd, MERCER GLOBAL ADVISORS /ADV, based on the most recent SEC filings. ORMP trades on the Nasdaq exchange and files with the SEC under CIK 1176309. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ORMP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ORAMED PHARMACEUTICALS INC. directly from SEC EDGAR.
Net Income
Q3 2026
$38.3M
Free Cash Flow
Q3 2026
$-2.9M
Get alerted when ORMP's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ORAMED PHARMACEUTICALS INC. including:
Top Institutional Holders of ORMP
BML Capital Management, LLC
$10.8M3,167,231 shAquamarine Financial (Cayman) Ltd
$7.2M2,112,312 shMERCER GLOBAL ADVISORS INC /ADV
$6.5M1,910,540 shGem Investment Advisors, LLC
$5.6M1,640,069 shMurchinson Ltd.
$4.5M1,315,294 shBOOTHBAY FUND MANAGEMENT, LLC
$2.0M600,716 shMARSHALL WACE, LLP
$882.7K259,611 shRathbones Group PLC
$792.3K233,018 shDIMENSIONAL FUND ADVISORS LP
$537.7K158,209 shWELLS FARGO & COMPANY/MN
$535.8K157,586 sh
| Fund | Value | Shares |
|---|---|---|
| BML Capital Management, LLC | $10.8M | 3,167,231 |
| Aquamarine Financial (Cayman) Ltd | $7.2M | 2,112,312 |
| MERCER GLOBAL ADVISORS INC /ADV | $6.5M | 1,910,540 |
| Gem Investment Advisors, LLC | $5.6M | 1,640,069 |
| Murchinson Ltd. | $4.5M | 1,315,294 |
| BOOTHBAY FUND MANAGEMENT, LLC | $2.0M | 600,716 |
| MARSHALL WACE, LLP | $882.7K | 259,611 |
| Rathbones Group PLC | $792.3K | 233,018 |
| DIMENSIONAL FUND ADVISORS LP | $537.7K | 158,209 |
| WELLS FARGO & COMPANY/MN | $535.8K | 157,586 |
Put ORMP on your watchlist
Track score changes the day ORAMED PHARMACEUTICALS INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ORMP a good stock to buy?
13F Pro's AI-powered analysis of ORAMED PHARMACEUTICALS INC. (ORMP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ORMP are available on the ORMP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ORMP?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ORMP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ORAMED PHARMACEUTICALS INC.'s investment landscape.